ERBB2 and breast cancer: Retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) database of BC patients indicates that the ERBB2+ subtype along with triple-negative BC account for more than 50% of cases of distant metastasis, which preferentially metastasizes to brain, bone, liver, and lungs [3].